LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
MRM
MEDIROM Healthcare Technologies Inc.
There isn't enough reported data to score MRM yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate MRM's fundamentals.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
MRM PE Valuation
MRM has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
MRM Forward outlook
There aren't enough analyst estimates for MRM to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
MRM Earnings Per Share
MRM and LCID do not have enough comparable growth data to identify a winner.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over MRM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
MRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3.8M | -87% |
| Q2 2025 | $20.3M | -6.7% |
| Q4 2024 | $30.2M | +35% |
| Q2 2024 | $21.8M | +7.2% |
| Q4 2023 | $22.5M | -5.8% |
| Q2 2023 | $20.3M | +106% |
| Q4 2022 | $23.9M | +132% |
| Q2 2022 | $9.9M | -26% |
MRM's revenue has held roughly level: $4M last quarter, down 83% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 12% | +14 points |
| Q2 2025 | -28% | -19 points |
| Q4 2024 | 13% | +6.2 points |
| Q2 2024 | -18% | -13 points |
| Q4 2023 | -2.3% | +12 points |
| Q2 2023 | -9.6% | +15 points |
| Q4 2022 | 6.6% | +60 points |
| Q2 2022 | -4.9% | +59 points |
MRM's operating margin was 12% last quarter, up 14 points from the same quarter a year ago.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
MRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$2.3M | +$2.7M |
| Q4 2024 | -$6.8M | -$6.2M |
| Q2 2024 | -$5M | -$865.8K |
| Q4 2023 | -$634.9K | +$2.4M |
| Q2 2023 | -$4.2M | -$3.2M |
| Q4 2022 | -$3M | -$2.2M |
| Q2 2022 | -$1M | +$197.1K |
| Q4 2021 | -$825K | -4728% |
MRM has burned cash in most quarters: −$15M over the past year, against −$9M the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has the edge over MRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
MRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +3K shares |
| 1 year | +45% | +2.5M shares |
| 3 years | +85% | +3.6M shares |
MRM has 8M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MRM Net Leverage
MRM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
MRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 6.2 | Oversold |
MRM's weekly RSI is 22 (oversold) and its Stochastic is 6 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
MRM PE vs Consumer Cyclical Sector
| Metric | MRM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MRM has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
MRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 35% below |
| 20 week MA | $0.74 | 62% below |
| 50 week MA | $1.15 | 76% below |
| 100 week MA | $1.28 | 78% below |
| 200 week MA | $3.21 | 91% below |
MRM is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has the edge over MRM on returns for 2026, with the stronger performance.
MRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.4 | $6.26 | -57% |
| 2022 | $6.26 | $5.58 | -11% |
| 2023 | $5.58 | $5.72 | +2.5% |
| 2024 | $5.72 | $1.05 | -82% |
| 2025 | $1.05 | $2.21 | +110% |
| 2026 YTD | $2.21 | $0.28 | -87% |
MRM's yearly returns have swung widely, from +110% in 2025 to −82% in 2024. It's down 87% so far in 2026.